{"id":"foflox4","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Anemia"},{"rate":"15-25","effect":"Mucositis"},{"rate":"10-20","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOFLOX4 is a combination chemotherapy regimen where 5-fluorouracil (5-FU) inhibits thymidylate synthase to disrupt DNA synthesis, folinic acid enhances 5-FU efficacy by stabilizing its binding to the enzyme, and oxaliplatin forms DNA cross-links to prevent replication. This triple-agent approach targets rapidly dividing cancer cells through multiple mechanisms of cytotoxicity.","oneSentence":"FOFLOX4 is a chemotherapy regimen combining fluorouracil, folinic acid (leucovorin), and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:08.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (metastatic or locally advanced)"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT01035385","phase":"PHASE3","title":"Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2009-09","conditions":"Colorectal Cancer, Liver Metastasis","enrollment":340}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FOFLOX4","genericName":"FOFLOX4","companyName":"Guangdong Provincial People's Hospital","companyId":"guangdong-provincial-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOFLOX4 is a chemotherapy regimen combining fluorouracil, folinic acid (leucovorin), and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Colorectal cancer (metastatic or locally advanced), Gastric cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}